Dabigatran and Argatroban Diametrically Modulate Thrombin Exosite Function

PLoS One. 2016 Jun 15;11(6):e0157471. doi: 10.1371/journal.pone.0157471. eCollection 2016.

Abstract

Thrombin is a highly plastic molecule whose activity and specificity are regulated by exosites 1 and 2, positively-charged domains that flank the active site. Exosite binding by substrates and cofactors regulates thrombin activity by localizing thrombin, guiding substrates, and by inducing allosteric changes at the active site. Although inter-exosite and exosite-to-active-site allostery have been demonstrated, the impact of active site ligation on exosite function has not been examined. To address this gap, we used surface plasmon resonance to determine the effects of dabigatran and argatroban, active site-directed inhibitors, on thrombin binding to immobilized γA/γA-fibrin or glycoprotein Ibα peptide via exosite 1 and 2, respectively, and thrombin binding to γA/γ'-fibrin or factor Va, which is mediated by both exosites. Whereas dabigatran attenuated binding, argatroban increased thrombin binding to γA/γA- and γA/γ'-fibrin and to factor Va. The results with immobilized fibrin were confirmed by examining the binding of radiolabeled thrombin to fibrin clots. Thus, dabigatran modestly accelerated the dissociation of thrombin from γA/γA-fibrin clots, whereas argatroban attenuated dissociation. Dabigatran had no effect on thrombin binding to glycoprotein Ibα peptide, whereas argatroban promoted binding. These findings not only highlight functional effects of thrombin allostery, but also suggest that individual active site-directed thrombin inhibitors uniquely modulate exosite function, thereby identifying potential novel mechanisms of action.

MeSH terms

  • Allosteric Regulation / drug effects
  • Antithrombins / pharmacology
  • Arginine / analogs & derivatives
  • Binding Sites
  • Biocatalysis / drug effects
  • Blood Coagulation / drug effects
  • Catalytic Domain
  • Dabigatran / pharmacology*
  • Fibrin / metabolism
  • Fibrinogen / metabolism*
  • Humans
  • Pipecolic Acids / pharmacology*
  • Protein Binding / drug effects
  • Substrate Specificity
  • Sulfonamides
  • Surface Plasmon Resonance
  • Thrombin / metabolism*

Substances

  • Antithrombins
  • Pipecolic Acids
  • Sulfonamides
  • Fibrin
  • Fibrinogen
  • Arginine
  • Thrombin
  • Dabigatran
  • argatroban

Grants and funding

This work was funded in part by grants from the Canadian Institutes of Health Research (MOP-136820 and FRN-3992) and the Heart and Stroke Foundation of Canada (T6357). C.H.Y. is supported by a Doctoral Scholarship from the Canadian Institutes of Health Research. J.I.W. holds the Canada Research Chair (Tier I) in Thrombosis and the Heart and Stroke Foundation J. Fraser Mustard Chair in Cardiovascular Research at McMaster University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.